Sandra "Sandi" Peterson, group worldwide chairman of Johnson & Johnson (J&J), stands for a photograph at the J&J consumer healthcare products plant in Lititz, Pennsylvania, U.S., on Wednesday, June 18, 2014. Johnson & Johnson, the world's biggest health-care products company, beat expectations in its first-quarter earnings release in April and raised its 2014 forecast by focusing on new drugs and reducing its reliance on medical devices. J&J is expected to release second-quarter earnings figures on July 15. Photographer: Andrew Harrer/Bloomberg via Getty ImagesAndrew Harrer—Bloomberg via Getty Images
- TitleGroup Worldwide Chair
- AffiliationJohnson & Johnson
Peterson has expanded her reach at the world’s largest health care company, adding medical devices to a portfolio that includes brands ranging from Band-Aid to Tylenol. She now oversees some $40 billion in revenue—more than half of J&J’s total. She’s been on an acquisition tear, shepherding six deals in the consumer business in the past 18 months and 23 in medical devices during the first half of 2017. The moves are meant to help transform J&J, whose stock has underperformed the S&P over the past 12 months.Read our July 2016 feature “Can Big Still Be Beautiful?” for more on how Peterson is helping to transform Johnson & Johnson.
Company Financials (2016, or most recently completed fiscal year)
|Market Value as of 9/14/17 ($M)||360139.1|